Doxorubicinone-d3

• Product Name Alternative:

  Adriamycin aglycone-d3; Adriamycinone-d3

• UNSPSC Description:

  Doxorubicinone-d3 is the deuterium labeled Doxorubicinone. Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin[1]. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.

• Target Antigen:

  Endogenous Metabolite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  OC1=C(C2=C(C(C3=O)=C1C(C4=CC=CC(OC([2H])([2H])[2H])=C34)=O)O)C[C@](O)(C[C@@H]2O)C(CO)=O

• Molecular Weight:

  417.38

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]M Joerger, et al. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol. 2005 May;55(5):488-96.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported